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Abstract 
Background: In 2012, alarmingly high rates of oral artemisinin monotherapy availability and use were detected 
along Eastern Myanmar, threatening efforts to halt the spread of artemisinin resistance in the Greater Mekong 
Subregion (GMS), and globally. The aim of this paper is to exemplify how the use of supply side evidence generated 
through the ACTwatch project shaped the artemisinin monotherapy replacement malaria (AMTR) project’s design 
and interventions to rapidly displace oral artemisinin monotherapy with subsidized, quality-assured ACT in the private 
sector.
Methods: The AMTR project was implemented as part of the Myanmar artemisinin resistance containment (MARC) 
framework along Eastern Myanmar. Guided by outlet survey and supply chain evidence, the project implemented 
a high-level subsidy, including negotiations with a main anti-malarial distributor, with the aim of squeezing oral 
artemisinin monotherapy out of the market through price competition and increased availability of quality-assured 
artemisinin-based combinations. This was complemented with a plethora of demand-creation activities targeting 
anti-malarial providers and consumers. Priority outlet types responsible for the distribution of oral artemisinin mono-
therapy were identified by the outlet survey, and this evidence was used to target the AMTR project’s supporting 
interventions.
Conclusions: The widespread availability and use of oral artemisinin monotherapy in Myanmar has been a serious 
threat to malaria control and elimination in the country and across the region. Practical anti-malarial market evidence 
was rapidly generated and used to inform private sector approaches to address these threats. The program design 
approach outlined in this paper is illustrative of the type of evidence generation and use that will be required to 
ensure effective containment of artemisinin drug resistance and progress toward regional and global malaria elimina-
tion goals.
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Background
The malaria burden in Myanmar is far higher than in any 
other country in South East Asia, accounting for most of 
the reported malaria cases in the Greater Mekong Sub-
region (GMS) [1]. Malaria has been the leading cause 
of morbidity and mortality in Myanmar for over two 
decades [2]. Around 35 million people, or 70  % of the 
population, are at risk of malaria, and 25 million are con-
sidered at high risk. Malaria risk is higher in forested and 
hilly areas such as the areas in Eastern Myanmar, areas 
mainly inhabited by ethnic minorities [3]. The most vul-
nerable are migrant workers, particularly those who work 
in and around forests, in industries such as gem-mining, 
logging, agriculture and construction.
Artemisinin-based combination therapy (ACT) has 
helped to reduce the global burden of malaria, however 
this is now threatened by the emergence of malaria par-
asites that are resistant to artemisinin [4, 5]. Of grave 
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concern is that artemisinin-resistant Plasmodium fal-
ciparum has been identified on the eastern borders of 
Myanmar [6] and, most recently, along the border with 
India [7]. Myanmar is thus critical to global efforts to 
contain resistance, but the complexities are vast. There is 
extensive migration in high transmission areas, increas-
ing the spread of resistance. The country has been faced 
with over 60 years of civil conflict in some border areas. 
Inadequate investment in the health system—overall and 
for malaria control in particular—has posed challenges to 
effective malaria case management [8].
In 2011, there was little information on the private sec-
tor in Myanmar, but it was estimated that most malaria 
treatments in Myanmar were accessed directly from 
this sector, similar to other markets in the region [9]. 
Low levels of government investment and conflict, par-
ticularly along the remote border areas where malaria is 
highest, meant that health services were of limited qual-
ity or availability. Thus, it was anticipated that local drug 
sellers and other private sector provider types were typi-
cally sought—after for treatment [8]. There was also con-
cern that most malaria was not only self-diagnosed but 
treated inappropriately with incomplete courses of oral 
artemisinin monotherapy. The use of oral artemisinin 
monotherapy, incomplete courses   and, in particular, 
substandard drugs was of concern given emerging drug 
resistance.
To address this situation, in 2010, the Government of 
Myanmar, under the Myanmar artemisinin resistance 
containment (MARC) framework, developed a com-
prehensive set of interventions to address the spread of 
artemisinin resistance in Eastern Myanmar [3]. As part of 
the private sector initiative, in 2012, Population Services 
International (PSI), a large, US-based NGO, designed and 
implemented the evidence-based artemisinin monother-
apy replacement (AMTR) malaria project with support 
from the UK Department For International Development 
(DFID), the Bill and Melinda Gates Foundation (BMGF) 
and Good Ventures. At a global level, the AMTR pro-
ject aimed to ensure a firewall against the spread of arte-
misinin resistance through South East Asia, India and to 
Africa; and at a national level, it aimed to increase the 
availability and supply of high quality, affordable ACT, 
thus reducing the burden of P. falciparum in the endemic 
areas  and  moving the country from control towards 
elimination of malaria. In its simplest form, the AMTR 
project approach was to get subsidized, high-quality-
assured, first-line ACT into the private sector through 
key suppliers and distributors, with the aim of squeez-
ing oral artemisinin monotherapy out of the market due 
to price competition, increased availability of ACT, and 
other demand-creation activities.
This paper documents how two critical research stud-
ies informed the development and design of the AMTR 
project across Eastern Myanmar and describes the pro-
gram activities that were developed as a result of the 
malaria landscape in 2010–2012, using evidence that 
these research studies generated.
The studies
Prior to the program implementation, two supply side 
surveys, a supply chain study and an outlet survey were 
conducted in Eastern Myanmar to investigate the private 
sector anti-malarial landscape, with the aim of using the 
findings to inform programming decisions and imple-
mentation activities. The studies are described in this 
sub-section.
The supply chain study
In 2010, PSI/Myanmar conducted a supply chain study 
to document the distribution chain for anti-malarials 
in Eastern Myanmar. The aim of the supply chain study 
was to provide a snapshot of the current market for anti-
malarial drugs in Eastern Myanmar: how the supply 
chain functioned, how the anti-malarial medicines were 
bought and sold, which anti-malarials were dominating 
the market, and estimated prices to patients as well as 
mark-ups.
The supply chain study was conducted primarily to 
provide input into the proposal development for the pro-
ject and was used as formative research to help shape the 
project development and rationale. A short, open-ended 
interview guide was developed to ascertain information 
from key informants across different levels of the supply 
chain. Questions included: where the anti-malarials med-
icines were purchased from, the quantity/amount pur-
chased, the quantity/amount typically distributed, and 
the type of anti-malarial medicine. Providers who sold 
to patients were asked the typical selling price. Snowball 
and purposive sampling methods were used. The assess-
ment utilized a bottom-up approach to identify respond-
ents. Initially, respondents (key informants) at the 
bottom end of the supply chain were interviewed, namely 
general retailers and mobile providers. This was the first 
wave of data collection. A second wave of interviews 
was implemented with pharmacists and wholesalers that 
had been identified in the first wave of data collection 
by the general retailers and mobile providers. Finally, a 
third wave of data collection was implemented with the 
higher-order wholesalers and distributors referred to by 
the key informants in the second wave of interviews. The 
assessment allowed for a rapid assessment of the sup-
ply chain. In total, 34 key informants were interviewed: 
11 mobile providers, 8 general retailers, 9 pharmacies, 3 
wholesalers and 3 importers and distributors. Data were 
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analyzed and transcribed using standard qualitative the-
matic methods but focused specifically on identifying the 
main distributor(s) and a diagrammatic qualitative repre-
sentation of the supply chain structure.
The first study took place along the eastern border, the 
area with the highest risk of drug resistance. A second 
study was conducted close to the China border, in Kachin 
and Shan States, to investigate whether medicines from 
China played a significant part in the local market. Both 
studies confirmed a very similar pattern. A core find-
ing was that 70 % of the artemisinin monotherapy in the 
anti-malarial market was supplied by one distributor: 
AA Medical Products Limited. The main product being 
supplied by this wholesaler was called ‘AA Artesunat®, 
(Fig.  1), although other artemisinin monotherapy prod-
ucts were identified such as Artem® (Artemether injection 
and tablets), Arthesis®, AA-Artemether® and Artemodi® 
(all oral artemisinin tablets). This distributor not only had 
control of the artemisinin monotherapy market but also 
had a sophisticated distribution mechanism that pen-
etrated outlets that were directly serving patients, such 
as general retailers and pharmacies. Many providers in 
towns and cities in the area were supplied directly by the 
AA Medical Products Limited distribution mechanism. 
It was also observed that half of the sales were funneled 
through wholesalers, and the artemisinin monotherapy 
distribution was therefore relatively centralized.
Regarding information on sales from the supplier, 
almost all of the anti-malarials distributed by AA Medi-
cal Products Limited were oral artemisinin monotherapy. 
It was estimated that more than 100,000 strips (of 12 
tablets) of artesunate monotherapy were distributed per 
month on average—and around 1.2 million doses were 
imported per annum.
Other evidence gathered across the supply chain helped to 
set the eventual price of the subsidized, quality-assured ACT. 
Data showed that the average mark-up of anti-malarial drugs 
across the different levels of the supply chain varied. Among 
outlets serving patients, it was feasible to determine how 
many oral artemisinin tablets were typically sold to patients 
and at what price. It was estimated that the market price of a 
full adult course of artesunate, comprised of 12 tablets, was 
around 2400 (Myanmar) Kyat. However, providers reported 
that they typically only gave two or three tablets to the patient, 
preferring to sell individual pills rather than a complete dose 
(with two to three pills sold for around 500 Kyat or $0.40 in 
2012). Interviews with providers suggested that each strip of 
artesunate monotherapy was typically used to treat two to 
three malaria-suspected patients. This evidence on price of 
sale to patients, as well as mark-ups along the distribution 
chain, helped the program to calculate in a backward fashion 
a recommended retail price for the quality-assured ACT.
Other evidence from key informant interviews con-
ducted with patients indicated that the private sector 
played a major role in malaria treatment in Myanmar. Most 
commonly, patients described purchasing anti-malar-
ial medicines from local private sector outlets and were 
unlikely to receive a malaria diagnostic test. If high-quality 
ACT treatment drugs were available at these outlets, they 
were described as prohibitively expensive. Providers also 
reported that they gave clients ‘what they wanted’, and this 
was typically artemisinin in tablet form. The root cause of 
the sale of incomplete treatment regimens was most often 
described as ‘cost’, as patients could not afford a full course.
The outlet survey
A cross-sectional outlet survey based on the ACTwatch 
methodology was conducted across 26 townships in 
Fig. 1 Samples of common artesunate monotherapy identified by the supply chain
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Eastern Myanmar between March and May, 2012 [10]. 
The objective of the ACTwatch outlet survey was to 
investigate the availability, price and market share of 
anti-malarial medicines across private sector outlets. 
The methods and study objectives have been described 
in detail elsewhere [11–13]. Briefly, a census of all outlets 
with the potential to sell anti-malarials was conducted 
in selected townships and wards across Eastern Myan-
mar. Among eligible outlets, that is, outlets that stocked 
anti-malarial medicines on the day of survey or in the 
previous 3  months, a full audit of anti-malarials was 
conducted. Information on the brand and generic name, 
strength, amount sold in the previous week as well as the 
price was collected for each anti-malarial medicine. A 
provider interview assessing provider knowledge and dis-
pensing practices was also implemented.
A total of 3658 private sector outlets with the poten-
tial to sell anti-malarials were screened. In the context 
of Myanmar, these included private facilities and com-
munity health workers, pharmacies, general retailers and 
mobile providers (or sometimes described as itinerant 
drug vendors who do not typically operate from a fixed 
location and may or may not have some medical back-
ground/training). Of the 3658 outlets screened, 32  % 
stocked at least one anti-malarial at the time of the study, 
including 82 % of private health facilities (N = 273), 73 % 
of community health workers (N =  348), 79  % of phar-
macies (N = 454), 55 % of mobile providers (N = 290), 
and 15  % of general retailers (N  =  2292). Availabil-
ity was relatively low among general retailers (village 
stores  and grocery stores) although they were the most 
numerous outlet type in the census. The availability of 
quality-assured ACT varied across different anti-malar-
ial-stocking outlet types: private health facility (55  %), 
community health worker (76 %), pharmacy (7 %), mobile 
provider (8  %) and general retailer (3  %). Availability of 
oral artemisinin monotherapy was higher across all key 
outlet types: pharmacy (86  %), mobile provider (30  %), 
general retailer (81 %) (see Fig. 2). Priority outlets—phar-
macies, general retailers, and mobile providers—were 
outlets that received additional supportive interventions, 
namely production promotion through PSI.
Observing market share of different classes of anti-
malarials, oral artemisinin monotherapy accounted for 
33 % of the total market share. Within outlets, oral arte-
misinin was most commonly sold by pharmacies (more 
than 45 % of the market share), mobile providers (38 % of 
the market share), and general retailers (32 % of the mar-
ket share) (Fig. 3). Across these three outlet types, market 
share of quality-assured ACT was less than 5  % among 
mobile providers and general retailers, and was report-
edly not sold or distributed in the previous week by phar-
macies. Provider knowledge of the first-line treatment 
for malaria was exceptionally low among anti-malarial-
stocking pharmacies, mobile providers and general retail-
ers (<10 %) compared to private facilities and community 
health workers (58.2 and 54.9  %, respectively). Another 
finding was that providers often report cutting blisters of 
pills, lending to cocktail formulations or other sub-opti-
mal treatment regimens, and this was most common in 
pharmacies, general retailers and among mobile provid-
ers [10].
In summary, the supply side data indicate that there 
were a number of barriers to ensuring access to the first-
line ACT treatment for malaria, including availability 
and price of ACT. The supply side data indicated wide 
spread use and distribution of other anti-malarials to 
treat malaria, in particular oral artemisinin monotherapy, 
which is acknowledged as a major bottleneck in contain-
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Fig. 2 Availability of different classes of anti-malarials, Eastern Myanmar 2012
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findings from the supply chain and the outlet survey were 
used to inform the AMTR project strategy for oral arte-
misinin monotherapy replacement in the private sector 
and are discussed in the next section.
How evidence and policy shifts were used to develop 
and design the AMTR project activities
Enabling environment
In 2010, at the time of the supply chain rapid assessment, 
artemisinin monotherapy was legal and registered by the 
Government of Myanmar, although the national guide-
lines encouraged use of a combination therapy. Findings 
from the supply chain provided evidence regarding the 
distribution of oral artemisinin monotherapy in East-
ern Myanmar. PSI, along with other organizations and 
partners within the MARC framework, shared the find-
ings with the NMCP program managers as a means to 
help senior officials within the government advocate for 
tightening the importation and regulation of artemisinin 
monotherapy so that only intravenous, intramuscu-
lar and rectal suppository formulations of artemisinin 
for the treatment of severe malaria would be permitted. 
Subsequently, the importation of oral formulations of 
artesunate and artemether was banned in Myanmar in 
December 2011, and August 2012, respectively, by the 
Food and Drug Administration  (FDA). However, oral 
artemisinin monotherapy was still legal to purchase in 
Myanmar while existing stocks were used up.
Theory of change
The AMTR project was also guided by a theory of 
change, pertaining to how the interventions and activi-
ties implemented by PSI would shape the market over 
time. While it is acknowledged at the time of writing that 
some of these assumptions have changed based on new 
epidemiological data, the framework helped to guide and 
visualize the project implementation and vision of suc-
cess. The framework was developed using information 
from the supply chain as well as other key resources from 
the Ministry of Health and the World Health Organiza-
tion. The following situation was described (see Fig.  4): 
(1) Based on the number of malaria cases visited in pub-
lic health facilities and the number of annual oral arte-
misinin monotherapy drugs imported into the country, 
it was roughly estimated that there were 5 million fever 
cases in the PSI target area—equivalent to a two-week 
fever prevalence of 1.8 % among the general population; 
(2) Of these fever cases, 44 % test positive for P. falcipa-
rum and 78 % of all malaria cases are infections with P. 
falciparum; (3) The majority of all cases were treated in 
the private sector (estimated to be around 70 %); (4) Of 
malaria treatments from the private sector, the major-
ity of treatments given were oral artemisinin monother-
apy, and most patients only took a partial dose; (5) This 
low dose of oral artemisinin monotherapy was limited 
in its effects on malaria transmission and represented 
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Fig. 3 Market share of anti-malarials distributed in the past week, Eastern Myanmar 2012
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enhancing the likelihood of selecting resistant strains, 
and; (6) Reversing this situation by replacing oral arte-
misinin monotherapy in the private sector with full treat-
ment courses of quality-assured ACT through the AMTR 
project would then significantly contribute to the resist-
ance-containment efforts.
Stopping oral artemisinin monotherapy distribution
Based on the findings of the supply chain survey, in 2012, 
PSI engaged the major private sector supplier of arte-
misinin, AA Medical Products Limited, in an agreement 
to purchase highly-subsidized, pre-packaged, quality-
assured ACT from PSI. This was expected to rapidly 
replace oral artemisinin monotherapy in at least 70 % of 
all private sector malaria treatment providers in Eastern 
Myanmar, especially given the extensive distribution net-
works that were already in place.
Developing the right products
According to national treatment guidelines, the ACT 
artemether-lumefrantrine (AL) was indicated for the treat-
ment of P. falciparum malaria. WHO prequalified AL 
tablets were procured through a competitive bid and over-
branded with the brand names Supa Arte® and Artel®. 
Both products were first-line treatment for uncomplicated 
malaria and packaged according to four child/adolescent 
and adult weight ranges. In addition to this, an unbranded 
generic ACT was also distributed in the private sector 
directly to PSI-franchised Sun Quality Health Clinics. Hav-
ing two different brands helped to ensure that providers 
further down the supply chain had a choice between dif-
ferent malaria treatments. This facilitated the progressive 
replacement of oral artemisinin monotherapy by ACT in 
the private sector and also created healthy competition.
Both brands were marked with a quality seal—the 
Padonmar (lotus leaf ), designed to identify all quality-
assured ACT imported and distributed in Myanmar, 
allowing for the program to promote the anti-malarial 
medicine rather than a particular formulation, manufac-
turer, distributor or/and brand. The NMCP and the FDA 
were also closely involved in this process, as the seal was 
meant to be used by all partners distributing quality-
assured ACT in the country—regardless of the donor 
funding or project location. Thus, any WHO-approved 
ACT that was part of the national treatment guidelines 
was branded and identified using the lotus leaf seal.
A key advantage of the quality seal was that it also ena-
bled PSI and other partners to potentially respond to 
changing national guidelines of first-line ACT without 
eroding brand equity, should sentinel surveillance sug-
gest that partner drug efficacy was deteriorating. It was 
also created to help both providers and consumers iden-
tify the best possible treatment for P. falciparum malaria. 
In addition, the 30  % of the market that was not being 
reached by the key drug distributors would still be able 
to know that they were accessing a quality, first-line ACT. 
The quality seal was developed with participation from 
over 14 stakeholder organizations, including the NMCP, 
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Fig. 4 PSI Theory of change during the project inception
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How the quality‑assured ACT were manufactured 
and distributed
The quality-assured ACT were procured directly by PSI 
through a competitive bid. The imported ACT were 
over-packaged (additional packaging with consumer 
instructions) and over-branded in Myanmar in PSI’s own 
warehouse (Fig.  5). The over-packaging was done with 
the aim of deterring health care providers from cutting 
the blister packets and using ineffective single doses, as 
evidence from the supply surveys suggested this was a 
common practice.
After over-packaging, AA Medical Products Limited 
collected the quality-assured ACT branded products 
from the PSI warehouse and distributed them through 
their existing networks.
Ensuring affordable anti‑malarials
Both of the quality-assured ACT brands were highly sub-
sidized so that patients were motivated to purchase them 
over other anti-malarial medicines. The subsidy was pro-
vided to the extent that the price of a complete dose of 
quality-assured ACT was equivalent to the same price 
of a partial dose (2–3 tablets) of oral artemisinin mono-
therapy, which was typically taken by febrile patients 
with suspected malaria. The recommended retail selling 
price was 500 Kyat, reflecting a subsidy of 80  % of the 
regular non-subsidized price. The price was determined 
based on the information from the supply chain survey, 
including average mark-ups across different levels and 
the number of tablets typically sold to consumers by 
lower-level suppliers. Acknowledging that people with 
suspected malaria can typically afford around 500 Kyat, 
the program calculated the price in a backward fashion, 
from the lower-level suppliers to the wholesale/distribu-
tor level, to determine a price that AA Medical Products 
Limited would use to sell to its wholesalers. The recom-
mended retail price for quality-assured ACT was then 
monitored using the annual outlet surveys, reporting on 
the percentage of providers that sold a full course quality-
assured ACT at or below 500 Kyat. Data from subsequent 
outlet surveys revealed that this assumption was correct, 
with the majority of priority outlets (~80 %) selling a full 
course of quality-assured ACT at or below 500 Kyat.
Creating consumer demand
At a national level, mass media communication cam-
paigns were implemented to encourage the public to 
demand quality ACT from drug sellers. These cam-
paigns raised awareness of the need to seek prompt 
treatment  and to take a full course of an effective and 
affordable ACT and highlighted the problems associ-
ated with consumption of counterfeit drugs. At the time 
of implementation, the majority of febrile patients had 
been using monotherapies for over a decade. The main 
purpose of the communication campaign was to create 
demand for a full course of pre-packaged quality-assured 
ACT rather than loose tablets (and incomplete doses) of 
a monotherapy. A key aim was to ensure that patients 
could easily identify a ‘quality-assured’ ACT from other 
products already in the market and being sold by provid-
ers, including other ACT that may not be quality-assured. 
Thus, a core component of the communication campaign 
was to create demand and awareness of the ‘lotus leaf ’ 
quality seal. All communication and campaign mes-
sages were around WHO/NMCP-recommended quality-
assured ACT, which could be recognized by the lotus leaf 
quality seal. To ensure messaging resonated with a vari-
ety of target audiences, the communication campaigns 
included a variety of people, such as migrant workers and 
rubber tappers, all of whom spoke to the benefits of the 
quality seal and of adherence to the full course.
Targeting the key areas and promoting provider behavior 
change
The AMTR project was national in scope, as the supply 
chain intervention reached all states and regions with 
quality-assured ACT. However, in the eastern part of 
the country, including the MARC high-risk zones (zones 
identified as most at risk of artemisinin resistance in 
Myanmar), PSI designated a target area for an intensified 
communications campaign. The target area covered a 
population of a little over ten million people and included 
all of the MARC-defined high-risk zones and surround-
ing and linking townships.
In this target area, ACT sales and mass media were 
reinforced by pharmaceutical detailing operations 
through PSI product promoters. Product promoters 
implemented provider behavior change and interpersonal 
communication as a means to amplify an increase in 
ACT uptake in the supply chain. At the project inception, 
PSI recruited and trained over 75 product promoters to 
specifically target the different priority outlets [pharma-
cies, general retailers and mobile providers (see below 
for further discussion)] and to promote awareness and Fig. 5 Over-packaging ACT treatments in PSI the warehouse
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knowledge of quality-assured, effective ACT among pro-
viders from these outlets. The product promoters spoke 
local languages, which helped to ensure ethnic minor-
ity communities were reached. The product promoters 
provided information on general malaria transmission 
and prevention, malaria drug resistance, and stocking 
and dispensing decisions and also provided key messages 
around the need to use ACT and the harm associated 
with incorrect drug regimes. Product promoters also 
shared information regarding the risks associated with 
use of oral artemisinin monotherapy and the benefits of 
prescribing a full course of quality-assured ACT. They 
specifically discouraged the stocking of oral artemisinin 
monotherapy and promoted the replacement of exist-
ing stocks with quality-assured ACT. Product promoters 
were also responsible for provision of information, edu-
cation and communication (IEC) materials pertaining to 
malaria treatment, as well as job aid materials. They also 
collected routine sales data of quality-assured ACT and 
oral artemisinin monotherapy.
Product promoters did not sell ACT directly to the 
priority outlets  but did provide free samples of quality-
assured ACT on their first visit and then established a 
link between the outlets and the supply points by pro-
viding providers with a list of the wholesalers and mid-
wholesalers from the nearest towns or areas where 
quality-assured ACT could be purchased. They also pro-
vided providers with a recommended retail selling price. 
Product promoters visited all of the AMTR priority out-
lets in their assigned township every quarter.
As well as targeting the priority outlets, product pro-
moters also visited the wholesalers in the surrounding 
towns to ensure the availability of quality-assured ACT 
and to identify and report back on any potential stock-
out issues.
Targeting the ‘right’ outlets
The outlet survey showed that there were five types 
of non-governmental outlets that sold or distributed 
anti-malarial medicines in Eastern Myanmar, including 
oral artemisinin monotherapy. The census approached 
used by the ACTwatch study identified the relevancy 
of community health workers, private health workers, 
pharmacies, general retailers and mobile providers as 
anti-malarial-stocking outlets. The last three categories 
were recognized as being largely unregulated, meaning 
that these outlets did not receive any access to formal 
training or commodities from the government or other 
non-governmental organizations. This was also reflected 
in the outlet survey findings, which demonstrated rela-
tively high availability of oral artemisinin monotherapy 
and low ACT availability among the anti-malarial stock-
ing pharmacies, general retailers and mobile providers 
and high volumes of oral artemisinin monotherapy 
being distributed by these outlet types (and low-level of 
knowledge about recommended treatment for malaria). 
Thus, rather than reaching all outlet types, and given the 
urgency to implement rapid changes in the supply side 
across the Eastern areas, PSI product promoters targeted 
key outlet types: pharmacies, general retailers and mobile 
providers with the aforementioned provider supervision 
and regulation. To engage with mobile providers, details 
of their fixed location were obtained by the product 
promoters, and follow-up meetings were planned dur-
ing the product promoter’s visit. As telephone coverage 
increased, the mobile providers were increasingly con-
tacted by phone to secure follow-up visits.
Nationwide sales
While a targeted behavior change approach was imple-
mented in Eastern Myanmar, sales of ACT were nation-
wide (Fig. 6). The rationale for this was both practical and 
epidemiological. Practically, containing private sector 
ACT sales within a particular region of Myanmar would 
have been extremely difficult; experience has shown that 
market forces draw the product where there is demand, 
and malaria is widespread in Myanmar, with 70 % of the 
population living in endemic areas. Epidemiologically, 
national sales of quality-assured ACT also made the most 
Fig. 6 A map of the PSI target and sales area
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sense. Although there was no evidence of resistance out-
side of the eastern half of the country at the time of the 
implementation, it was recognized that continued avail-
ability and use of oral artemisinin monotherapy in west-
ern Myanmar could surely promote both the spread of, 
and potentially the de novo emergence of, artemisinin 
resistance. See Fig. 5, for an overview of the distribution 
system.
Discussion
The AMTR project has been implemented since 2012, 
following supply chain study findings that showed high 
levels of oral artemisinin monotherapy sale and distri-
bution in Myanmar. Since project inception, substantial 
improvements in the anti-malarial market landscape, 
have been observed and demonstrate the value of a 
high-level subsidy combined with supportive interven-
tions. Recent findings from three survey rounds (2012, 
2013 and 2014) illustrate the success of the project, with 
notable increases in quality-assured ACT availability and 
market share and declines in oral artemisinin monother-
apy availability and distribution, mainly among priority 
outlets in the intervention area and, to a lesser extent, 
among priority outlets in the comparison area [14]. In 
addition to the outlet survey findings, there are several 
other lessons from the AMTR project that may be helpful 
for projects in other malaria-endemic settings struggling 
with private sector readiness and performance for appro-
priate malaria case management.
First, while the AMTR project included measuring 
change in supply side indicators over time, an important 
component was to influence and monitor the demand 
side, including patient fever treatment-seeking behav-
ior, ACT treatment for suspected malaria and patient 
adherence to ACT treatment. However, due to low and 
declining rates of malaria prevalence in Myanmar, stand-
ard methods using population-based surveys to measure 
these indicators have not been useful in this context [15]. 
Despite screening several thousand households, suffi-
cient numbers of patients with recent fever and patients 
who reportedly received anti-malarial treatment have 
been unobtainable through standard survey sampling 
methods. To address this issue, project indicators were 
revised, and demand-side evaluation methodologies were 
updated. The project now uses research methods to fol-
low up with patients who received an ACT from priority 
and non-priority outlets to measure adherence.
Another challenge relates to drug policy for oral arte-
misinin monotherapy. Although banned by the FDA, 
there was no ban on oral artemisinin monotherapy sales 
or distribution and no mechanism for drug recall. Related 
to this, companies who were awarded 5-year distribu-
tion licenses just prior to the ban could legally continue 
to distribute for the duration of the license. While the 
AMTR project sought to remove all oral artemisinin 
monotherapy from the market, the lack of an enabling 
environment was a threat to the success of the interven-
tion. Furthermore, the long shelf-life of oral artemisinin 
monotherapy means that this product can remain on the 
shelves for a long period. Conversely, the PSI-distributed 
quality-assured ACT has a shorter shelf life. Given the 
drop in Myanmar’s malaria caseload, providers may be 
incentivized to stock a malaria medicine with a longer 
shelf life and for which they can sell at a similar price to 
quality-assured ACT. In fact, recent outlet survey data 
from 2015 shows a rise in the availability of oral arte-
misinin monotherapy from 2014. Indeed, among priority 
outlets in the intervention area, availability of oral arte-
misinin monotherapy increased from 10  % in 2014 to 
30 % in 2015. Similarly, market share of oral artemisinin 
monotherapy increased from around 21  % in 2014 to 
26  % in 2015 [16]. This shows that, while substantial 
gains have been made over recent years, oral artemisinin 
monotherapy still stubbornly persists in Myanmar’s anti-
malarial market, calling for the need for a complete ban 
on the importation, licensing, sale and distribution of 
oral artemisinin monotherapy as well as measures to 
enforce the ban.
Rapid diagnostic test (RDT) scale-up has only recently 
been introduced into the project and has been a chal-
lenging project component to implement. Changes in 
the political leadership and policies on the sale and dis-
tribution of malaria RDTs meant that, rather than using 
the private sector ACT supply chain for RDTs, RDTs 
had to be distributed free-of-charge in the private sector 
through product promoters. The AMTR project focused 
on launching a training program for private health pro-
viders to ensure correct RDT use, as well as mass media 
and interpersonal communication campaigns. The suc-
cess of this arm of the intervention is yet to be evalu-
ated, but the project’s need for flexibility and response to 
changing policies at the national level is important.
Finally, Myanmar’s anti-malarial market is constantly 
changing, making the application of appropriate market 
development strategies challenging and dynamic. Pro-
jecting commodities and supply chain management is a 
constant challenge. With declining malaria prevalence 
rates and increased coverage of malaria RDTs, the pro-
ject strives to maintain a balance between the risk of drug 
expiry versus the risk of ACT stock-out. This is further 
complicated given challenges with estimating sales and 
outlet coverage between two distributors and geographi-
cal challenges in reaching certain areas of the country 
that are less accessible due to conflict and instability. 
There is a need to continually review available evidence 
and adjust strategies, inputs and targeting.
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Conclusions
Prior to the AMTR project intervention, in 2012, oral 
artemisinin monotherapy was available in over 50  % of 
anti-malarial-stocking outlets and accounted for 33  % 
of the market share. A rapid intervention was urgently 
required to address the availability and distribution of 
oral artemisinin monotherapy due to the threat to arte-
misinin drug efficacy. This required working with the pri-
vate sector and primarily with unregulated outlet types 
in Myanmar in an attempt to change the most under-
performing outlets, where oral artemisinin monotherapy 
accounted for almost half of the market share among 
those outlet types. Several lessons can be learned from 
the AMTR project that will be useful for other countries 
that are interested in redefining their anti-malarial mar-
ket and engaging with the private sector.
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